A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hanson's Yeast) in Chinese Women Aged 9-45 Years
Conditions:  HPV Infection;  HPV-Related Cervical Carcinoma Interventions:  Biological: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha);  Biological: Placebo Sponsors:  National Vaccine and Serum Institute, China;  Chengdu Institute of Biological Products Co.,Ltd.;  Simoon Record Pharma Information Consulting Co., Ltd;  Guangxi Center for Disease Control and Prevention;  Beijing Kantorico Statistical Technology Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Cervical Cancer Vaccine | China Health | Clinical Trials | Gardasil | Genital Warts | Human Papillomavirus (HPV) | Pharmaceuticals | Research | Statistics | Vaccines | Women